These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 28566683)
1. Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses. Madan-Lala R; Pradhan P; Roy K Sci Rep; 2017 May; 7(1):2530. PubMed ID: 28566683 [TBL] [Abstract][Full Text] [Related]
2. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity. Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684 [TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory effects of Toll-like receptor ligands as adjuvants in establishing a novel mouse model for pemphigus vulgaris. Gao C; Liu M; Xin Y; Zeng Y; Yang H; Fan X; Zhao C; Zhang B; Zhang L; Li JJ; Zhao M; Wang Z; Lu Q Clin Transl Med; 2024 Jul; 14(7):e1765. PubMed ID: 39031979 [TBL] [Abstract][Full Text] [Related]
4. Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders. Thomas S; Pak J; Doss-Gollin S; Ryff K; Beijnen E; Pedersen GK; Christensen D; Levy O; van Haren SD J Mol Biol; 2024 Feb; 436(4):168446. PubMed ID: 38242283 [TBL] [Abstract][Full Text] [Related]
5. Directing the immune system with chemical compounds. Mancini RJ; Stutts L; Ryu KA; Tom JK; Esser-Kahn AP ACS Chem Biol; 2014 May; 9(5):1075-85. PubMed ID: 24690004 [TBL] [Abstract][Full Text] [Related]
6. Understanding how combinatorial targeting of TLRs and TNFR family costimulatory members promote enhanced T cell responses. Shinde P; Bharat V; Rodriguez-Oquendo A; Zhou B; Vella AT Expert Opin Biol Ther; 2018 Oct; 18(10):1073-1083. PubMed ID: 30169979 [TBL] [Abstract][Full Text] [Related]
7. From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Netea MG; Van der Meer JW; Sutmuller RP; Adema GJ; Kullberg BJ Antimicrob Agents Chemother; 2005 Oct; 49(10):3991-6. PubMed ID: 16189071 [No Abstract] [Full Text] [Related]
8. Toward precision adjuvants: optimizing science and safety. Nanishi E; Dowling DJ; Levy O Curr Opin Pediatr; 2020 Feb; 32(1):125-138. PubMed ID: 31904601 [TBL] [Abstract][Full Text] [Related]
10. Toll-like Receptor Agonist Conjugation: A Chemical Perspective. Ignacio BJ; Albin TJ; Esser-Kahn AP; Verdoes M Bioconjug Chem; 2018 Mar; 29(3):587-603. PubMed ID: 29378134 [TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor agonists: are they good adjuvants? Gnjatic S; Sawhney NB; Bhardwaj N Cancer J; 2010; 16(4):382-91. PubMed ID: 20693851 [TBL] [Abstract][Full Text] [Related]
12. Lipid-Mediated Insertion of Toll-Like Receptor (TLR) Ligands for Facile Immune Cell Engineering. Zhang MH; Slaby EM; Stephanie G; Yu C; Watts DM; Liu H; Szeto GL Front Immunol; 2020; 11():560. PubMed ID: 32425924 [TBL] [Abstract][Full Text] [Related]
13. Precision nanoscale patterning of TLR ligands for improved cancer immunotherapy. Tseng CY; Murtada F; Chou LYT Cell Rep Methods; 2024 May; 4(5):100782. PubMed ID: 38772343 [TBL] [Abstract][Full Text] [Related]